{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:47:37Z","timestamp":1792853257201,"version":"4.5.0"},"reference-count":177,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2025.e00805","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T04:44:50Z","timestamp":1765514690000},"page":"e00805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of primary adult-onset neurodegenerative cerebellar ataxias"],"prefix":"10.1016","volume":"23","author":[{"given":"Leonardo E.","family":"Ariello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.W.","family":"Rastall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana S.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/brain\/40.4.461","article-title":"The symptoms of acute cerebellar injuries due to gunshot injuries","volume":"40","author":"Holmes","year":"1917","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12311-013-0511-x","article-title":"Consensus paper: the cerebellum\u2019s role in movement and cognition","volume":"13","author":"koziol","year":"2014","journal-title":"Cerebellum"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1474-4422(09)70305-9","article-title":"Sporadic ataxia with adult onset: classification and diagnostic criteria","volume":"9","author":"Klockgether","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00805_bib4","series-title":"Chapter 2 acquired cerebellar ataxias and differential diagnosis","first-page":"61","volume":"31","author":"Klockgether","year":"2007"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00805_bib5","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/mds.23559","article-title":"Milestones in ataxia","volume":"26","author":"Klockgether","year":"2011","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1474-4422(07)70054-6","article-title":"Clinical features and molecular genetics of autosomal recessive cerebellar ataxias","volume":"6","author":"Fogel","year":"2007","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14802\/jmd.16028","article-title":"Episodic ataxias: clinical and genetic features","volume":"9","author":"Choi","year":"2016","journal-title":"J Mov Disord"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00805_bib8","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1093\/brain\/awm126","article-title":"Primary episodic ataxias: diagnosis, pathogenesis and treatment","volume":"130","author":"Jen","year":"2007","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1749-6632.2011.06158.x","article-title":"Cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS): a review of the clinical features and video-oculographic diagnosis","volume":"1233","author":"Szmulewicz","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12311-009-0144-2","article-title":"Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias","volume":"9","author":"Matilla-Due\u00f1as","year":"2010","journal-title":"Cerebellum"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00805_bib11","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/mds.29032","article-title":"Paving the way toward meaningful trials in ataxias: an ataxia global initiative perspective","volume":"37","author":"Klockgether","year":"2022","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/WCO.0000000000000774","article-title":"Cerebellar ataxias: an update","volume":"33","author":"Manto","year":"2020","journal-title":"Curr Opin Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40265-023-01874-9","article-title":"Omaveloxolone: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of omaveloxolone in friedreich\u2019s ataxia: delayed-start analysis of the MOXIe extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00687","article-title":"SLX-100, a novel immediate release formulation of 4-aminopyridine, for the treatment of spinocerebellar ataxia 27B (SCA27B), an orphan disease","volume":"22","author":"Chappell","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00805_bib17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1212\/WNL.0000000000005055","article-title":"Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia [RETIRED] : report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"90","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00805_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1212\/WNL.0000000000005055","article-title":"Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia [RETIRED] : report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"90","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.sc.3101515","article-title":"Professor heinrich sebastian Frenkel: a forgotten founder of rehabilitation medicine","volume":"42","author":"Zwecker","year":"2004","journal-title":"Spinal Cord"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00805_bib20","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1007\/s00415-020-09938-6","article-title":"guang Balance and coordination training for patients with genetic degenerative ataxia: a systematic review","volume":"268","author":"He","year":"2021","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12311-020-01181-z","article-title":"The efficacy and safety of transcranial direct current stimulation for cerebellar ataxia: a systematic review and meta-analysis","volume":"20","author":"Chen","year":"2021","journal-title":"Cerebellum Lond Engl"},{"key":"10.1016\/j.neurot.2025.e00805_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1491142","article-title":"Effects of physiotherapy on degenerative cerebellar ataxia: a systematic review and meta-analysis","volume":"15","author":"Matsugi","year":"2025","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1545968311425918","article-title":"Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases","volume":"26","author":"Miyai","year":"2012","journal-title":"Neurorehabilitation Neural Repair"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/1545968314522350","article-title":"A home balance exercise program improves walking in people with cerebellar ataxia","volume":"28","author":"Keller","year":"2014","journal-title":"Neurorehabilitation Neural Repair"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00805_bib25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/mds.27437","article-title":"Neurorehabilitation therapy in spinocerebellar ataxia type 2: a 24-week, rater-blinded, randomized, controlled trial","volume":"33","author":"Rodr\u00edguez-D\u00edaz","year":"2018","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib26","doi-asserted-by":"crossref","first-page":"7816","DOI":"10.1038\/s41598-018-26109-w","article-title":"A randomized controlled pilot trial of game-based training in individuals with spinocerebellar ataxia type 3","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00805_bib27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/mdc3.14036","article-title":"Effect of a home-base core stability exercises in hereditary Ataxia. A randomized controlled trial. A pilot randomized controlled trial","volume":"11","author":"Cabanas-Vald\u00e9s","year":"2024","journal-title":"Mov Disord Clin Pract"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ana.27130","article-title":"Goal-directed rehabilitation versus standard care for individuals with hereditary cerebellar ataxia: a multicenter, single-blind, randomized controlled superiority trial","volume":"97","author":"Milne","year":"2025","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ncl.2020.01.008","article-title":"An overview of the current state and the future of Ataxia treatments","volume":"38","author":"Kwei","year":"2020","journal-title":"Neurol Clin"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1474-4422(23)00068-6","article-title":"Autosomal dominant cerebellar ataxias: new genes and progress towards treatments","volume":"22","author":"Coarelli","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00805_bib31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","article-title":"Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models","volume":"7","author":"Moore","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"issue":"36","key":"10.1016\/j.neurot.2025.e00805_bib32","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1107198108","article-title":"The Ataxin-2 protein is required for microRNA function and synapse-specific long-term olfactory habituation","volume":"108","author":"McCann","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib33","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ana.26713","article-title":"Antisense oligonucleotide silencing reverses abnormal neurochemistry in spinocerebellar ataxia 3 mice","volume":"94","author":"McLoughlin","year":"2023","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/jnnp.53.4.297","article-title":"Idiopathic cerebellar ataxia of late onset: natural history and MRI morphology","volume":"53","author":"Klockgether","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib35","article-title":"Prevalence of RFC1 -mediated spinocerebellar ataxia in a North American ataxia cohort","volume":"6","author":"Aboud","year":"2020","journal-title":"Neurol Genet"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ajhg.2022.11.015","article-title":"An intronic GAA repeat expansion in FGF14 causes the autosomal-dominant adult-onset ataxia SCA27B\/ATX-FGF14","volume":"110","author":"Rafehi","year":"2023","journal-title":"Am J Hum Genet"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00805_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35841","article-title":"Safety and efficacy of Acetyl-DL-Leucine in certain types of cerebellar ataxia: the ALCAT randomized clinical crossover trial","volume":"4","author":"Feil","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00805_bib38","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S1474-4422(15)00201-X","article-title":"Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Romano","year":"2015","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00805_bib39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1212\/WNL.0b013e3181d31e23","article-title":"Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial","volume":"74","author":"Ristori","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0022-510X(83)90008-4","article-title":"Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations","volume":"61","author":"Sobue","year":"1983","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jnnp-2019-322168","article-title":"Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials","volume":"91","author":"Nishizawa","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/jnnp.61.3.259","article-title":"Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study","volume":"61","author":"Botez","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00805_bib43","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1212\/WNL.0b013e3181d31e23","article-title":"Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial","volume":"74","author":"Ristori","year":"2010","journal-title":"Neurology"},{"issue":"7_supplement_1","key":"10.1016\/j.neurot.2025.e00805_bib44","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1212\/WNL.0000000000205167","article-title":"Matching-adjusted indirect comparison of Troriluzole versus untreated natural history cohort in spinocerebellar ataxia (S35.009)","volume":"102","author":"Beiner","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00805_bib45","series-title":"Trial of BHV-4157 (Troriluzole) in adult subjects with spinocerebellar ataxia. ClinicalTrials.gov identifier: NCT03701399. Dispon\u00edvel em","year":"2023"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0b013e318225ab07","article-title":"A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias","volume":"77","author":"Strupp","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib47","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000001017","article-title":"Fampridine and acetazolamide in EA2 and related familial EA: a prospective randomized placebo-controlled trial","volume":"11","author":"Muth","year":"2021","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1212\/01.WNL.0000078893.41040.56","article-title":"Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study","volume":"61","author":"Strupp","year":"2003","journal-title":"Neurology"},{"issue":"7_suppl ment","key":"10.1016\/j.neurot.2025.e00805_bib49","article-title":"A pilot, randomized, Placebo-Controlled, trial of lithium in spinocerebellar ataxia type 2 (S43.005)","volume":"80","author":"Sacc\u00e0","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib50","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/mds.25803","article-title":"A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease","volume":"29","author":"Saute","year":"2014","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/WNL.0b013e318247cc7a","article-title":"A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3","volume":"78","author":"Zesiewicz","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00805_bib52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.parkreldis.2016.03.005","article-title":"Safety and efficacy of valproic acid treatment in SCA3\/MJD patients","volume":"26","author":"Lei","year":"2016","journal-title":"Parkinsonism Relat Disorders"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/mds.30050","article-title":"Potential disease-modifying effects of Ganglioside GM1 pulse treatment on spinocerebellar ataxia type 3, a parallel-group, double-blind, randomized, controlled trial","volume":"40","author":"Chen","year":"2025","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1034\/j.1600-0404.2001.00299.x","article-title":"Clinical trial of acetazolamide in SCA6, with assessment using the Ataxia Rating scale and body stabilometry: clinical trial of acetazolamide for SCA6","volume":"104","author":"Yabe","year":"2001","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib55","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2010.168","article-title":"A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia","volume":"67","author":"Lynch","year":"2010","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2217\/nmt-2018-0013","article-title":"Double-blind randomized and controlled trial of EPI-743 in Friedreich\u2019s Ataxia","volume":"8","author":"Zesiewicz","year":"2018","journal-title":"Neurodegener Dis Manag"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00805_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35841","article-title":"Safety and efficacy of Acetyl-DL-Leucine in certain types of cerebellar ataxia: the ALCAT randomized clinical crossover trial","volume":"4","author":"Feil","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0022-510X(02)00009-6","article-title":"Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration","volume":"195","author":"Mori","year":"2002","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3727\/096368916X694373","article-title":"Treatment of spinocerebellar ataxia with mesenchymal stem cells: a phase I\/IIa clinical study","volume":"26","author":"Tsai","year":"2017","journal-title":"Cell Transplant"},{"key":"10.1016\/j.neurot.2025.e00805_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105076","article-title":"GAA-FGF14 disease: defining its frequency, molecular basis, and 4-aminopyridine response in a large downbeat nystagmus cohort","volume":"102","author":"Pellerin","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neurot.2025.e00805_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120849","article-title":"Case series: downbeat nystagmus in SCA27B","volume":"454","author":"Shirai","year":"2023","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/WNO0b013e3181b416de","article-title":"The spinocerebellar ataxias","volume":"29","author":"Paulson","year":"2009","journal-title":"J Neuro Ophthalmol"},{"key":"10.1016\/j.neurot.2025.e00805_bib63","series-title":"Biohaven provides update on phase 3 clinical trial evaluating troriluzole for spinocerebellar ataxia (SCA) [press release]","year":"2022"},{"issue":"15_supplment","key":"10.1016\/j.neurot.2025.e00805_bib65","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1212\/WNL.96.15_supplement.2837","article-title":"Analysis of 96 week, long-term open label extension phase of study BHV4157-201: a phase IIb\/III, randomized, double-blind, placebo-controlled trial of the safety and efficacy of troriluzole in adult subjects with spinocerebellar ataxia (2837)","volume":"96","author":"Beiner","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00805_bib66","unstructured":"Bushara, K. O. Real-world analysis of disease progression in spinocerebellar ataxia treated with troriluzole. Cerebellum. 23(1):45-56."},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib67","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2310151","article-title":"Trial of N -Acetyl- l -Leucine in Niemann\u2013Pick disease type C","volume":"390","author":"Bremova-Ertl","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib68","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/jcph.6133","article-title":"Determination of vatiquinone drug-drug interactions, as CYP450 perpetrator and victim, using physiologically based pharmacokinetic (PBPK) modeling and simulation","volume":"65","author":"Lee","year":"2025","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib69","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ng0793-221","article-title":"Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1","volume":"4","author":"Orr","year":"1993","journal-title":"Nat Genet"},{"issue":"21","key":"10.1016\/j.neurot.2025.e00805_bib70","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123193","article-title":"Antisense oligonucleotide\u2013mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles","volume":"3","author":"Friedrich","year":"2018","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00805_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14797","article-title":"Effects of cerebellar repetitive transcranial magnetic stimulation plus physiotherapy in spinocerebellar ataxias \u2013 a randomized clinical trial","volume":"30","author":"Grobe-Einsler","year":"2024","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib73","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3390\/biom13050788","article-title":"Therapeutic strategies for spinocerebellar ataxia type 1","volume":"13","author":"Kerkhof","year":"2023","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00805_bib74","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.26356","article-title":"Cerebellar transcranial direct current stimulation in patients with ataxia: a double-blind, randomized, sham-controlled study: CEREBELLAR t DCS IN ATAXIC DISORDERS","volume":"30","author":"Benussi","year":"2015","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib75","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.brs.2016.11.001","article-title":"Long term clinical and neurophysiological effects of cerebellar transcranial direct current stimulation in patients with neurodegenerative ataxia","volume":"10","author":"Benussi","year":"2017","journal-title":"Brain Stimul"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib76","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12883-019-1379-2","article-title":"Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3 (SCA3-tDCS): rationale and protocol of a randomized, double-blind, sham-controlled study","volume":"19","author":"Maas","year":"2019","journal-title":"BMC Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib77","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s12311-023-01578-6","article-title":"Comparing cerebellar tDCS and cerebellar tACS in neurodegenerative ataxias using wearable sensors: a randomized, double-blind, Sham-controlled, triple-crossover trial","volume":"23","author":"Libri","year":"2023","journal-title":"Cerebellum"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib78","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/jnnp.72.1.124","article-title":"Transcranial magnetic stimulation alleviates truncal ataxia in spinocerebellar degeneration","volume":"72","author":"Shiga","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00805_bib79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fneur.2019.00073","article-title":"Repetitive transcranial magnetic stimulation in spinocerebellar ataxia: a pilot randomized controlled trial","volume":"10","author":"Manor","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2025.e00805_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2020.09.001","article-title":"Effects of cerebellar transcranial magnetic stimulation on ataxias: a randomized trial","volume":"80","author":"Fran\u00e7a","year":"2020","journal-title":"Parkinsonism Relat Disorders"},{"key":"10.1016\/j.neurot.2025.e00805_bib81","article-title":"Effects of repetitive transcranial magnetic stimulation on cerebellar metabolism in patients with spinocerebellar ataxia type 3","volume":"14","author":"Chen","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2025.e00805_bib82","article-title":"Short-term efficacy of repetitive transcranial magnetic stimulation in SCA3: a prospective, randomized, double-blind, sham-controlled study","volume":"106","author":"Sikandar","year":"2023","journal-title":"Parkinsonism Relat Disorders"},{"key":"10.1016\/j.neurot.2025.e00805_bib83","article-title":"Effectiveness of high-frequency repetitive transcranial magnetic stimulation in patients with spinocerebellar ataxia type 3","author":"Zhou","year":"2023","journal-title":"J ECT"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib84","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(21)00457-9","article-title":"Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"21","author":"Coarelli","year":"2022","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib85","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s00415-021-10874-2","article-title":"Pharmacological and non-pharmacological management of spinocerebellar ataxia: a systematic review","volume":"269","author":"Yap","year":"2022","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib86","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s12311-021-01349-1","article-title":"Electrophysiological studies support utility of positive modulators of SK channels for the treatment of spinocerebellar ataxia type 2","volume":"21","author":"Egorova","year":"2022","journal-title":"Cerebellum"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib87","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/brain\/awab157","article-title":"Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia","volume":"144","author":"Benussi","year":"2021","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib88","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pneurobio.2011.11.006","article-title":"Toward understanding Machado\u2013Joseph disease","volume":"97","author":"Costa","year":"2012","journal-title":"Prog Neurobiol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib89","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40120-024-00625-6","article-title":"Video-based kinematic analysis of movement quality in a phase 3 clinical trial of troriluzole in adults with spinocerebellar ataxia: a post hoc analysis","volume":"13","author":"L\u2019Italien","year":"2024","journal-title":"Neurol Ther"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib90","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/brain\/awr047","article-title":"Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado\u2013Joseph disease","volume":"134","author":"Nascimento-Ferreira","year":"2011","journal-title":"Brain"},{"issue":"16","key":"10.1016\/j.neurot.2025.e00805_bib91","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/hmg\/ddae079","article-title":"A combination of chlorzoxazone and folic acid improves recognition memory, anxiety and depression in SCA3-84Q mice","volume":"33","author":"Marinina","year":"2024","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib92","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1007\/s12035-018-1331-2","article-title":"Citalopram reduces aggregation of ATXN3 in a YAC transgenic mouse model of Machado-Joseph disease","volume":"56","author":"Ashraf","year":"2019","journal-title":"Mol Neurobiol"},{"issue":"21","key":"10.1016\/j.neurot.2025.e00805_bib93","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123193","article-title":"Antisense oligonucleotide\u2013mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles","volume":"3","author":"Friedrich","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.neurot.2025.e00805_bib94","author":"Biogen"},{"issue":"7_supplement_1","key":"10.1016\/j.neurot.2025.e00805_bib95","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1212\/WNL.0000000000208349","article-title":"Deep brain stimulation in spinocerebellar ataxias: review (P6-3.020)","volume":"102","author":"Garg","year":"2024","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib96","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s12311-021-01326-8","article-title":"Safety and outcomes of dentate Nucleus deep brain stimulation for Cerebellar Ataxia","volume":"21","author":"Cury","year":"2021","journal-title":"Cerebellum"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib97","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/hmg\/6.8.1289","article-title":"SCA6 is caused by moderate CAG expansion in the alpha1A-voltage- dependent calcium channel gene","volume":"6","author":"Riess","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib98","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10038-004-0142-7","article-title":"A clinical and genetic study in a large cohort of patients with spinocerebellar ataxia type 6","volume":"49","author":"Takahashi","year":"2004","journal-title":"J Hum Genet"},{"key":"10.1016\/j.neurot.2025.e00805_bib99","series-title":"GeneReviews\u00ae","article-title":"GAA-FGF14-Related Ataxia","author":"Pellerin","year":"1993"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1504","article-title":"Spinocerebellar ataxia 27B: a novel, frequent and potentially treatable ataxia","volume":"14","author":"Pellerin","year":"2024","journal-title":"Clin Transl Med"},{"issue":"5254","key":"10.1016\/j.neurot.2025.e00805_bib102","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib103","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/nmt-2022-0011","article-title":"Friedreich ataxia: clinical features and new developments","volume":"12","author":"Keita","year":"2022","journal-title":"Neurodegener Dis Manag"},{"issue":"s1","key":"10.1016\/j.neurot.2025.e00805_bib104","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/jnc.12317","article-title":"Clinical features of Friedreich\u2019s ataxia: classical and atypical phenotypes","volume":"126","author":"Parkinson","year":"2013","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib105","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of omaveloxolone in friedreich\u2019s ataxia: delayed-start analysis of the MOXIe extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib106","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/acn3.51897","article-title":"Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data","volume":"11","author":"Lynch","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2025.e00805_bib108","article-title":"Vatiquinone treatment shows benefit across end points for Friedreich ataxia in Phase 3 MOVE-FA trial","year":"2024","journal-title":"NeurologyLive"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib109","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/jimd.12285","article-title":"Safety and efficacy of (+)-epicatechin in subjects with Friedreich\u2019s ataxia: a phase II , open-label, prospective study","volume":"44","author":"Qureshi","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2025.e00805_bib110","article-title":"Community update \u2013 LEXEO therapeutics announces positive interim phase 1\/2 data for LX2006 in Friedreich Ataxia Cardiomyopathy supporting advancement to registrational study","year":"2024","journal-title":"CureFA"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib111","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s42466-019-0038-9","article-title":"the EFACTS or NICOFA study group. Protocol of a randomized, double-, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA)","volume":"1","author":"Reetz","year":"2019","journal-title":"Neurol Res Pract"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib112","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/acn3.51971","article-title":"Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI -1601) in Friedreich\u2019s ataxia","volume":"11","author":"Clayton","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2025.e00805_bib113","unstructured":"A Study of ASP2016 in adults who have heart disease associated with Friedreich ataxia. Boston Children\u2019s Hospital. ClinicalTrials.gov Identifier: NCT06483802."},{"issue":"11","key":"10.1016\/j.neurot.2025.e00805_bib114","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.1007\/s00415-023-11868-y","article-title":"4-Aminopyridine improves real-life gait performance in SCA27B on a single-subject level: a prospective n-of-1 treatment experience","volume":"270","author":"Seemann","year":"2023","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00805_bib115","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nchembio815","article-title":"Histone deacetylase inhibitors reverse gene silencing in Friedreich\u2019s ataxia","volume":"2","author":"Herman","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib117","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ymgme.2012.03.012","article-title":"Recommendations for the diagnosis and management of Niemann\u2013Pick disease type C: an update","volume":"106","author":"Patterson","year":"2012","journal-title":"Mol Genet Metabol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib118","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13023-020-01363-2","article-title":"Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: a final report of the NPC Registry","volume":"15","author":"Patterson","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2025.e00805_bib119","series-title":"Episodic ataxias","first-page":"205","volume":"155","author":"Jen","year":"2018"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5334\/tohm.747","article-title":"Episodic ataxias: primary and secondary etiologies, treatment, and classification approaches","volume":"13","author":"Hassan","year":"2023","journal-title":"Tremor Hyperkinet Mov"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00805_bib121","doi-asserted-by":"crossref","first-page":"8826","DOI":"10.3390\/ijms24108826","article-title":"Novel genetic variants expand the functional, molecular, and pathological diversity of KCNA1 channelopathy","volume":"24","author":"Paulhus","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib122","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/epi.17659","article-title":"kcna1a mutant zebrafish model episodic ataxia type 1 (EA1) with epilepsy and show response to first-line therapy carbamazepine","volume":"64","author":"Dogra","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurot.2025.e00805_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.975849","article-title":"Case report: a novel loss-of-function pathogenic variant in the KCNA1 cytoplasmic N-terminus causing carbamazepine-responsive type 1 episodic ataxia","volume":"13","author":"Manville","year":"2022","journal-title":"Front Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00805_bib124","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/hmg\/6.11.1973","article-title":"Episodic Ataxia type 2 (EA2) and spinocerebellar Ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p","volume":"6","author":"Jodice","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"S1","key":"10.1016\/j.neurot.2025.e00805_bib125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00415-020-10190-1","article-title":"A novel pathogenic CACNA1A variant causing episodic ataxia type 2 (EA2) spectrum phenotype in four family members and a novel combined therapy","volume":"267","author":"Penkava","year":"2020","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib126","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000001017","article-title":"Fampridine and acetazolamide in EA2 and related familial EA: a prospective randomized placebo-controlled trial","volume":"11","author":"Muth","year":"2021","journal-title":"Neurol Clin Pract"},{"issue":"23","key":"10.1016\/j.neurot.2025.e00805_bib127","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000002743","article-title":"Pearls & Oy-sters: episodic ataxia type 2: case report and review of the literature","volume":"86","author":"Guterman","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib128","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1055\/s-0033-1334475","article-title":"Acetazolamide-Responsive Ataxia","volume":"32","author":"Kotagal","year":"2013","journal-title":"Semin Neurol"},{"key":"10.1016\/j.neurot.2025.e00805_bib129","first-page":"4655","article-title":"CANVAS an update: clinical presentation, investigation and management","volume":"24","author":"Szmulewicz","year":"2014"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-019-0372-4","article-title":"Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia","volume":"51","author":"Cortese","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurot.2025.e00805_bib131","series-title":"Feasibility of Pregabalin for the treatment of CANVAS-associated chronic cough","year":"2024"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib132","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01136-2019","article-title":"ERS guidelines on the diagnosis and treatment of chronic cough in adults and children","volume":"55","author":"Morice","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.neurot.2025.e00805_bib133","series-title":"Dentatorubral-pallidoluysian Atrophy: an update. Tremor Hyperkinetic Mov Tremor and Other Hyperkinetic Movements","author":"Carroll","year":"2018"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib134","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s00415-020-10218-6","article-title":"understanding the natural history and developing biomarkers to accelerate therapeutic trials in a globally rare repeat expansion disorder","volume":"268","author":"Chaudhry","year":"2021","journal-title":"J Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib135","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s00415-020-10218-6","article-title":"DRPLA: understanding the natural history and developing biomarkers to accelerate therapeutic trials in a globally rare repeat expansion disorder","volume":"268","author":"Chaudhry","year":"2021","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00805_bib136","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.29005","article-title":"The movement disorder Society criteria for the diagnosis of multiple System atrophy","volume":"37","author":"Wenning","year":"2022","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib137","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s13311-020-00890-x","article-title":"Current management and emerging therapies in multiple System atrophy","volume":"17","author":"Burns","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib138","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/WNF.0000000000000168","article-title":"Droxidopa and reduced Falls in a trial of parkinson disease patients with neurogenic orthostatic hypotension","volume":"39","author":"Hauser","year":"2016","journal-title":"Clin Neuropharmacol"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00805_bib139","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","article-title":"Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter Study","volume":"277","author":"Low","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.neurot.2025.e00805_bib140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMra1311488","article-title":"Multiple-System atrophy","volume":"372","author":"Fanciulli","year":"2015","journal-title":"N engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib141","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/ajh\/hpaa131","article-title":"Neurogenic orthostatic hypotension. Lessons from synucleinopathies","volume":"34","author":"Idiaquez","year":"2021","journal-title":"Am J Hypertens"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib142","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(13)70301-6","article-title":"Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial","volume":"13","author":"Low","year":"2014","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib143","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/mds.28923","article-title":"mTOR inhibition with sirolimus in multiple System atrophy: a randomized, Double-blind, placebo-controlled futility trial and 1-Year biomarker longitudinal analysis","volume":"37","author":"Palma","year":"2022","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib144","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.23612","article-title":"A randomized trial of mesenchymal stem cells in multiple system atrophy","volume":"72","author":"Lee","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00805_bib145","author":"Takeda"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00805_bib147","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/mds.29784","article-title":"Randomized phase I trial of the \u03b1-Synuclein antibody Lu AF82422","volume":"39","author":"Buur","year":"2024","journal-title":"Mov Disord"},{"issue":"7_supplement_1","key":"10.1016\/j.neurot.2025.e00805_bib149","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1212\/WNL.0000000000206596","article-title":"A phase 2 study of ATH434, a novel inhibitor of \u03b1-synuclein aggregation, for the treatment of multiple system atrophy (MSA) (P2-3.004)","volume":"102","author":"Stamler","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00805_bib150","series-title":"Teva\u2019s emrusolmin granted U.S. FDA fast track designation for treatment of multiple system atrophy [internet]","year":"2025"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib151","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/mdc3.14006","article-title":"Fatigue impacts quality of life in people with spinocerebellar ataxias","volume":"11","author":"Lai","year":"2024","journal-title":"Mov Disord Clin Pract"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib152","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/mdc3.13532","article-title":"A systematic review of the spectrum and prevalence of non-motor symptoms in adults with hereditary cerebellar ataxias","volume":"9","author":"Malek","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.neurot.2025.e00805_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105205","article-title":"Neuropsychiatric symptoms in spinocerebellar ataxias and friedreich ataxia","volume":"150","author":"Karamazovova","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00805_bib154","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1093\/brain\/awad157","article-title":"GAA- FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response","volume":"146","author":"Wilke","year":"2023","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib155","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2340\/16501977-2211","article-title":"Efficacy and safety of oral baclofen in the management of spasticity: a rationale for intrathecal baclofen","volume":"49","author":"Ertzgaard","year":"2017","journal-title":"J Rehabil Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib156","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11940-005-0008-0","article-title":"Current treatment of nystagmus","volume":"7","author":"Rucker","year":"2005","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.neurot.2025.e00805_bib157","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180054","article-title":"Cerebellar ataxia and intrathecal baclofen therapy: focus on patients\u2019 experiences","volume":"12","author":"Berntsson","year":"2017","journal-title":"Plos one"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib158","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mds.28355","article-title":"A chlorzoxazone-baclofen combination improves cerebellar impairment in spinocerebellar ataxia type 1","volume":"36","author":"Bushart","year":"2021","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib159","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archneur.61.1.35","article-title":"The parkinsonian phenotype of spinocerebellar ataxia type 2","volume":"61","author":"Lu","year":"2004","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00805_bib160","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00702-007-0746-0","article-title":"Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German competence network on Parkinson\u2019s disease","volume":"114","author":"W\u00fcllner","year":"2007","journal-title":"J Neural Transm"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00805_bib161","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1055\/s-0042-1755203","article-title":"Effect of speech therapy on quality of life in patients with spinocerebelar ataxia type 3","volume":"80","author":"Diaf\u00e9ria","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"issue":"22","key":"10.1016\/j.neurot.2025.e00805_bib162","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/WNL.0b013e3181c33adf","article-title":"Intensive coordinative training improves motor performance in degenerative cerebellar disease","volume":"73","author":"Ilg","year":"2009","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00805_bib163","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/mds.23222","article-title":"Long-term effects of coordinative training in degenerative cerebellar disease","volume":"25","author":"Ilg","year":"2010","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00805_bib164","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s00415-021-10874-2","article-title":"Pharmacological and non-pharmacological management of spinocerebellar ataxia: a systematic review","volume":"269","author":"Yap","year":"2022","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12311-022-01508-y","article-title":"Efficacy and safety of repetitive transcranial magnetic stimulation in cerebellar ataxia: a systematic review and meta-analysis","volume":"23","author":"Qiu","year":"2023","journal-title":"Cerebellum"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib166","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jamaneurol.2018.3639","article-title":"Effect of cerebellar stimulation on gait and balance recovery in patients with hemiparetic stroke: a randomized clinical trial","volume":"76","author":"Koch","year":"2019","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00805_bib167","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/JCMA.0000000000001243","article-title":"The efficacy of repetitive transcranial magnetic stimulation in patients with spinocerebellar ataxia: a systematic review and meta-analysis","volume":"88","author":"Lin","year":"2025","journal-title":"J Chin Med Assoc"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib168","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s12311-023-01628-z","article-title":"Efficacy and safety of repetitive transcranial magnetic stimulation in spinocerebellar ataxia type 3: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Qiu","year":"2023","journal-title":"Cerebellum"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib169","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12311-020-01181-z","article-title":"The efficacy and safety of transcranial direct current stimulation for cerebellar ataxia: a systematic review and meta-analysis","volume":"20","author":"Chen","year":"2021","journal-title":"Cerebellum"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib170","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s13311-022-01231-w","article-title":"Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3: a randomized, double-blind, sham-controlled trial","volume":"19","author":"Maas","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00805_bib171","article-title":"Cerebellar deep brain stimulation for movement disorders","volume":"175","author":"Sheng-Hong Tsengb","year":"2022","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00805_bib172","series-title":"Deep brain stimulation for tremor associated with underlying ataxia syndromes: a case series and discussion of issues. Tremor hyperkinetic Mov Tremor and Other Hyperkinetic Movements","author":"Oyama","year":"2014"},{"key":"10.1016\/j.neurot.2025.e00805_bib173","doi-asserted-by":"crossref","DOI":"10.3389\/dyst.2023.11363","article-title":"Case report: bilateral globus pallidum internus DBS for treating tremor and dystonia in spinocerebellar ataxia 17: a thirteen-year follow-up","volume":"2","author":"Wagle Shukla","year":"2023","journal-title":"Dystonia"},{"issue":"7_supplement_1","key":"10.1016\/j.neurot.2025.e00805_bib174","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1212\/WNL.0000000000208349","article-title":"Deep brain stimulation in spinocerebellar ataxias: review (P6-3.020)","volume":"102","author":"Garg","year":"2024","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00805_bib175","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12311-022-01403-6","article-title":"Mesenchymal stem cell therapy in the treatment of neurodegenerative cerebellar ataxias: a systematic review and meta-analysis","volume":"22","author":"Bhartiya","year":"2022","journal-title":"Cerebellum"},{"key":"10.1016\/j.neurot.2025.e00805_bib176","series-title":"Notice regarding announcement by partner Steminent Biotherapeutics Inc. of phase II clinical trial results in Taiwan for spinocerebellar ataxia treatment \u201cStemchymal\u00ae.\u201d","year":"2025"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00805_bib177","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.3390\/jcm9113654","article-title":"Therapeutic effects of human mesenchymal stem cells in a mouse model of Cerebellar ataxia with neuroinflammation","volume":"9","author":"Nam","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.neurot.2025.e00805_bib178","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.584277","article-title":"Mesenchymal stromal cells\u2019 therapy for polyglutamine disorders: where do we stand and where should we go?","volume":"14","author":"Barros","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"7650","key":"10.1016\/j.neurot.2025.e00805_bib179","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature22044","article-title":"Antisense oligonucleotide therapy for spinocerebellar ataxia type 2","volume":"544","author":"Scoles","year":"2017","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00805_bib180","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.3390\/ijms25084354","article-title":"AAV-mediated CAG-targeting selectively reduces polyglutamine-expanded protein and attenuates disease phenotypes in a spinocerebellar Ataxia mouse model","volume":"25","author":"Niewiadomska-Cimicka","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00805_bib181","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1089\/scd.2017.0209","article-title":"CRISPR\/Cas9-Targeted deletion of polyglutamine in spinocerebellar ataxia type 3-Derived induced pluripotent stem cells","volume":"27","author":"Ouyang","year":"2018","journal-title":"Stem Cell Dev"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00805_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102377","article-title":"CRISPR-Cas9-directed gene therapy for spinocerebellar ataxia type 1","volume":"35","author":"Micl\u0103u\u015f","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00805_bib183","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41398-021-01605-2","article-title":"CRISPR\/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells","volume":"11","author":"He","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00805_bib184","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.omtm.2020.04.018","article-title":"CRISPR-Cas9 gene editing of hematopoietic stem cells from patients with Friedreich\u2019s ataxia","volume":"17","author":"Rocca","year":"2020","journal-title":"Mol Ther, Methods Clin Dev"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00805_bib185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s13311-018-00696-y","article-title":"Genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias","volume":"16","author":"Buijsen","year":"2019","journal-title":"Neurotherapeutics"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:06:40Z","timestamp":1772856400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925002831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":177,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747925002831"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00805","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of primary adult-onset neurodegenerative cerebellar ataxias","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00805"}}